Hepatitis C therapy - A fast and competitive race

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 11, 2014, Pages 644-645

  Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 450; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; CILUPREVIR; DACLATASVIR; DASABUVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; ALPHA INTERFERON; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; RECOMBINANT PROTEIN;

ANTIVIRAL ACTIVITY; CARDIOTOXICITY; COST BENEFIT ANALYSIS; CRYSTAL STRUCTURE; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GOVERNMENT REGULATION; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIROGENESIS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETICS; HEPACIVIRUS;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84908499618     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.164     Document Type: Review

References (10)

1. Lange, C. M., Jacobson, I. M., Rice, C. M. & Zeuzem, S. Emerging therapies for the treatment of hepatitis C. EMBO Mol. Med. 6, 4-15 (2014).
2. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189 (2003).
3. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
4. Gane, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34-44 (2013).
5. Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216-224 (2012).
6. Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889-1898 (2014).
7. Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483-1493 (2014).
8. Feld, J. J. et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1594-1603 (2014).
9. Zeuzem, S. et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1604-1614 (2014).
10. Zeuzem, S. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 369, 630-639 (2013).